Table 5.
Association between the CYP2C19 681 genotypes and the death during the follow‐up period stratified by smoking history
| Multivariable adjusted OR (95% CI)a | |||
|---|---|---|---|
| Current smoking | Former smoking | Non‐smoking | |
| Total | |||
| GG | Reference | Reference | Reference |
| GA | 1.05 (0.61, 1.69) | 1.79 (0.68, 4.22) | 1.52 (0.53, 4.27) |
| AA | 1.12 (0.60, 2.31) | 4.38 (1.05, 9.40) | 5.06 (2.16, 11.49) |
| Haemorrhage | |||
| GG | Reference | Reference | Reference |
| GA | 1.12 (0.52, 1.77) | 1.67 (0.59, 4.51) | 1.12 (0.87, 3.87) |
| AA | 1.09 (0.48, 2.17) | 4.21 (1.14, 8.37) | 5.79 (1.91, 7.33) |
| Non‐haemorrhage | |||
| GG | Reference | Reference | Reference |
| GA | 1.21 (0.39, 1.94) | 1.72 (0.61, 4.18) | 1.33 (0.51, 4.80) |
| AA | 1.16 (0.53, 2.11) | 4.00 (1.01, 9.03) | 6.88 (2.00, 11.16) |
a
OR (95% CI): Odds ratio (95% confidence interval). Multivariable adjusted OR were adjusted for age, body mass index, onset of hypertension, diabetes, hyperlipidaemia, cerebrovascular disease, drinking, beta‐blocker usage, angiotensin‐converting enzyme inhibitor usage, angiotensin receptor blocker usage, prior percutaneous coronary intervention and prior coronary artery bypass grafting.
CI: confidence interval; GG: CYP2C19 681 wild‐type homozygotes; GA: CYP2C19 681 mutant heterozygotes; AA: CYP2C19 681 mutant homozygotes.